Neurocrine Biosciences (NASDAQ:NBIX) Receives "Outperform" Rating from William Blair

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities research analysts at William Blair in a report issued on Monday,RTT News reports.

Several other equities research analysts have also weighed in on the company. Royal Bank of Canada decreased their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a report on Friday, October 4th. HC Wainwright reiterated a "buy" rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research note on Monday. Wedbush restated an "outperform" rating and set a $148.00 price target on shares of Neurocrine Biosciences in a research note on Monday. Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Finally, StockNews.com cut shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $165.00.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock traded up $6.35 during trading hours on Monday, hitting $133.05. 1,651,300 shares of the company's stock traded hands, compared to its average volume of 869,946. The company has a fifty day simple moving average of $121.75 and a 200-day simple moving average of $130.59. The stock has a market capitalization of $13.47 billion, a price-to-earnings ratio of 35.79 and a beta of 0.34. Neurocrine Biosciences has a 12-month low of $110.95 and a 12-month high of $157.98.

Insider Activity at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of the business's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NBIX. Tri Ri Asset Management Corp bought a new position in shares of Neurocrine Biosciences during the 3rd quarter valued at $3,236,000. Tidal Investments LLC boosted its position in Neurocrine Biosciences by 52.8% during the third quarter. Tidal Investments LLC now owns 15,043 shares of the company's stock valued at $1,733,000 after buying an additional 5,197 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Neurocrine Biosciences during the third quarter valued at about $384,000. Sanctuary Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 103.9% in the third quarter. Sanctuary Advisors LLC now owns 7,649 shares of the company's stock worth $961,000 after buying an additional 3,898 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Neurocrine Biosciences in the third quarter worth about $1,985,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.